Inhibrx Biosciences Inc

INBX

58.390USD

-7.400-11.25%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Inhibrx Biosciences Inc's Score

Industry at a Glance

Industry Ranking

146 / 391

Overall Ranking

270 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Inhibrx Biosciences Inc Highlights

StrengthsRisks

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.30M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -6.46, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 9.81M shares, decreasing 14.20% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 623.08K shares of this stock.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

12.000

Target Price

-49.87%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Inhibrx Biosciences Inc is 7.31, ranking 104 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 31.40%.

Score

Industry at a Glance

Previous score

7.33

Change

-0.02



Financials

7.85

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.27

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.86

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.58

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Inhibrx Biosciences Inc is 6.16, ranking 319 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.46, which is -102.24% below the recent high of 0.14 and -21.04% above the recent low of -7.81.

Score

Industry at a Glance

Previous score

6.16

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 146/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Inhibrx Biosciences Inc is 6.00, ranking 340 out of 391 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 12.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

6.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Inhibrx Biosciences Inc is 6.80, ranking 130 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 71.49 and the support level at 51.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.31

Change

-0.51

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Inhibrx Biosciences Inc is 5.00, ranking 136 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 67.46%, representing a quarter-over-quarter increase of 1.80%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 1.44M shares, representing 9.84% of shares outstanding, with 20.30% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Perceptive Advisors LLC

1.33M

+35.77%

Viking Global Investors LP

Star Investors

1.44M

-19.58%

Sanofi SA

1.16M

--

Kayyem (Jon Faiz)

1.06M

-7.83%

Lappe Mark

950.41K

+2.70%

Morgan Stanley & Co. LLC

405.71K

+2255.79%

Hightower Advisors, LLC

871.76K

--

BlackRock Institutional Trust Company, N.A.

617.30K

-7.18%

The Vanguard Group, Inc.

Star Investors

594.92K

-0.59%

Eckelman (Brendan P)

513.89K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Inhibrx Biosciences Inc is 1.78, ranking 276 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Inhibrx Biosciences Inc

INBX

5.99 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment